Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Stem Cell Transplantation for Multiple Sclerosis
NCT00497952Phase 2Withdrawn
- Sponsor
- Talaris Therapeutics
- Start
- Jul 2007
- Primary completion
- Dec 2024
01
Overview
A Phase 2 trial of FCR001 in multiple sclerosis (MS), sponsored by Talaris Therapeutics. Planned start Jul 2007; status: withdrawn.
02
Drugs
FCR001
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT00497952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00497952.